Item Infomation
Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Hiroyuki, Seki | - |
| dc.contributor.author | Satoshi, Ideno | - |
| dc.contributor.author | Toshiya, Shiga | - |
| dc.date.accessioned | 2023-03-21T01:45:40Z | - |
| dc.date.available | 2023-03-21T01:45:40Z | - |
| dc.date.issued | 2023 | - |
| dc.identifier.uri | https://link.springer.com/article/10.1007/s00540-023-03174-8 | - |
| dc.identifier.uri | https://dlib.phenikaa-uni.edu.vn/handle/PNK/7006 | - |
| dc.description | CC BY | vi |
| dc.description.abstract | Although the recommended preoperative cessation period for sodium-glucose cotransporter 2 inhibitors (SGLT2is) changed in 2020 (from 24 h to 3–4 days preoperatively) to reduce the risk of SGLT2i-associated perioperative ketoacidosis (SAPKA), the validity of the new recommendation has not been verified. Using case reports, we assessed the new recommendation effectiveness and extrapolated precipitating factors for SAPKA. We searched electronic databases up to June 1, 2022 to assess SAPKA (blood pH < 7.3 and blood or urine ketone positivity within 30 days postoperatively in patients taking SGLT2i). | vi |
| dc.language.iso | en | vi |
| dc.publisher | Springer | vi |
| dc.subject | SGLT2is | vi |
| dc.subject | SAPKA | vi |
| dc.title | Sodium-glucose cotransporter 2 inhibitor-associated perioperative ketoacidosis: a systematic review of case reports | vi |
| dc.type | Book | vi |
| Appears in Collections | ||
| OER- Y học- Điều dưỡng | ||
Files in This Item:
